Status | Study |
Active, not recruiting |
Study Name: Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma Condition: MALT Lymphoma Date: 2013-03-06 Interventions: Drug: Chlorambucil Drug: Rituximab i.v. |
Terminated |
Study Name: 131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma Condition: Relapsed or Refractory Marginal Zone B-cell Lymphoma Date: 2012-09-04 Interventions: Drug: 131I-rituximab |
Completed |
Study Name: Endomicroscopy and Gastric MALT-lymphoma Condition: MALT-lymphoma Date: 2012-01-08 Interventions: Procedure: Confocal laser endomicroscopy |
Terminated |
Study Name: Salvage Therapy With High Dose Oral Clarithromycin in Relapsed or Refractory Extranodal Marginal Zone Lymphoma Condition: Lymphoma Date: 2012-01-06 Interventions: Drug: clarithromycin, oral, high dose 2 g/day clarithromycin (once a day) for 14 days followed by 7 days |
Completed |
Study Name: Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori Condition: Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive Date: 2010-12-20 Interventions: Drug: Rabeprazole Sodium The following 3 drugs are taken o |
Completed |
Study Name: Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL) Condition: Marginal Zone B-cell Lymphoma Date: 2010-07-15 Interventions: Drug: Everolimus Everolimus (tablets, 5 mg) is given orally at the dose of 10 mg/day from day 1 to day 2 |
Terminated |
Study Name: Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma Condition: Follicular Lymphoma Marginal Zone Lymphoma Date: 2010-02-11 Interventions: Drug: azacitidine Azacitidine |
Recruiting |
Study Name: Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) Condition: B-Cell Chronic Lymphocytic Leukemia Monoclonal B-Cell Lymphocytosis Date: 2009-06-17 |
Terminated |
Study Name: Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Treating Patients With Stage III or Stage IV Follicular Lymphoma or Marginal Zone Lymphoma Condition: Lymphoma Date: 2008-10-12 Interventions: Drug: Rituximab 375 mg/m2 IV i |
Completed |
Study Name: Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Condition: Waldenström Macroglobulinemia Lymphoplasmacytic Lymphoma Date: 2007-11-30 Interventions: Drug: Chlorambucil Chlorambuci |